Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Martin Glas, Theophilos Tzaridis et al.|The Lancet|2019Cited by 581
Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trialJohannes Weller, Niklas Schäfer, Theophilos Tzaridis et al.|The Lancet Oncology|2019Cited by 47
ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trialUlrich Herrlinger, Martin Glas, Theophilos Tzaridis et al.|Neuro-Oncology|2017Cited by 22
Endovascular thrombectomy in young patients with strokeJohannes Weller, Timo Uphaus, Christian H. Nolte et al.|International Journal of Stroke|2022Cited by 9
Endovascular Treatment for Acute Stroke in Cerebral Amyloid AngiopathyJohannes Weller, Christoph Trumm, Simon Jonas Enkirch et al.|Stroke|2021Cited by 8